.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Citi
AstraZeneca
Moodys
Teva
Julphar
Argus Health
US Army
Cantor Fitzgerald
McKinsey

Generated: September 20, 2017

DrugPatentWatch Database Preview

PEXEVA Drug Profile

« Back to Dashboard

What is the patent landscape for Pexeva, and what generic Pexeva alternatives are available?

Pexeva is a drug marketed by Sebela Ireland Ltd and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-nine patent family members in twenty-five countries.

The generic ingredient in PEXEVA is paroxetine mesylate. There are thirty drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the paroxetine mesylate profile page.

Summary for Tradename: PEXEVA

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list42
Clinical Trials: see list1
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:PEXEVA at DailyMed

Pharmacology for Tradename: PEXEVA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sebela Ireland Ltd
PEXEVA
paroxetine mesylate
TABLET;ORAL021299-001Jul 3, 2003RXYesNo► Subscribe► SubscribeY ► Subscribe
Sebela Ireland Ltd
PEXEVA
paroxetine mesylate
TABLET;ORAL021299-004Jul 3, 2003RXYesYes► Subscribe► Subscribe ► Subscribe
Sebela Ireland Ltd
PEXEVA
paroxetine mesylate
TABLET;ORAL021299-001Jul 3, 2003RXYesNo► Subscribe► Subscribe ► Subscribe
Sebela Ireland Ltd
PEXEVA
paroxetine mesylate
TABLET;ORAL021299-002Jul 3, 2003RXYesNo► Subscribe► Subscribe ► Subscribe
Sebela Ireland Ltd
PEXEVA
paroxetine mesylate
TABLET;ORAL021299-002Jul 3, 2003RXYesNo► Subscribe► SubscribeY ► Subscribe
Sebela Ireland Ltd
PEXEVA
paroxetine mesylate
TABLET;ORAL021299-003Jul 3, 2003RXYesNo► Subscribe► Subscribe ► Subscribe
Sebela Ireland Ltd
PEXEVA
paroxetine mesylate
TABLET;ORAL021299-004Jul 3, 2003RXYesYes► Subscribe► SubscribeY ► Subscribe
Sebela Ireland Ltd
PEXEVA
paroxetine mesylate
TABLET;ORAL021299-003Jul 3, 2003RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PEXEVA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sebela Ireland Ltd
PEXEVA
paroxetine mesylate
TABLET;ORAL021299-001Jul 3, 2003► Subscribe► Subscribe
Sebela Ireland Ltd
PEXEVA
paroxetine mesylate
TABLET;ORAL021299-002Jul 3, 2003► Subscribe► Subscribe
Sebela Ireland Ltd
PEXEVA
paroxetine mesylate
TABLET;ORAL021299-004Jul 3, 2003► Subscribe► Subscribe
Sebela Ireland Ltd
PEXEVA
paroxetine mesylate
TABLET;ORAL021299-003Jul 3, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: PEXEVA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,900,327 4-phenylpiperidine compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: PEXEVA

Country Document Number Estimated Expiration
South Korea20010013615► Subscribe
Norway317371► Subscribe
SloveniaEP0994872► Subscribe
Estonia9900570► Subscribe
Bulgaria103980► Subscribe
Estonia03970► Subscribe
Bulgaria64315► Subscribe
Germany69704679► Subscribe
Hungary0003141► Subscribe
Iceland7098► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Deloitte
Mallinckrodt
US Department of Justice
Farmers Insurance
Federal Trade Commission
Argus Health
Fish and Richardson
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot